Pimivalimab

DB16667InvestigationalProtein Based Therapies

Pimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen).

Mechanism: Pharmacologically active on Programmed cell death protein 1
Curator reviewed
Code names: JTX-4014

Resolves to

Compound

UNIIMA05AF40UOCAS2293951-22-9

Targets

Q15116PDCD1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pimivalimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account